News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

La Jolla Pharmaceutical Company (LJPC) Announces Completion Of Enrollment Of Phase 2 Extension Study Of GCS-100 In Chronic Kidney Disease



6/5/2014 9:14:35 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced that it has completed enrollment of GCS-100-CS-4003 (“4003 study”), its Phase 2 Extension study of GCS-100 in chronic kidney disease (“CKD”). The 4003 study was initiated to study the long-term safety and efficacy of GCS-100 in patients who completed the initial 12-week Phase 2 study (GCS-100-CS-4002). A total of 93 patients enrolled across 5 sites. Initial data from the 4003 Extension study is expected late this year.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES